Topic: How To Invest

Power Growth Investor Hotline – Friday, June 14, 2024

Article Excerpt

ELI LILLY AND COMPANY, $878.45, is a buy. The drugmaker (symbol LLY on New York) discovers, develops, manufactures, and markets human pharmaceutical products. This week, Lilly’s stock continued to hit new all-time highs as the drugmaker moved one step closer to winning approval for its Donanemab Alzheimer’s drug. This week, the drug received support from a panel of experts who advise the U.S. Food and Drug Administration (FDA). The panel unanimously voted that the medicine, developed by Lilly and known as Donanemab, appears to be an effective treatment for certain Alzheimer’s patients. The experts also concluded, by an 11-0 vote, that the drug’s benefits outweigh its risks, despite some safety concerns. Though the FDA isn’t required to follow the recommendations of its advisory committees, it typically does. Should the agency grant approval, Donanemab would be the third Alzheimer’s therapy of its kind cleared for the U.S. market. These medicines work by breaking up sticky, toxic collections of “amyloid beta,” a protein many researchers…